$1.01
-0.03-2.88%
At Close: -
$1.00
-0.01-0.99%
After Hours: 7:01 PM EDT
15 minutes delayed
Adaptimmune Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Adaptimmune Therapeutics using advanced sorting and filters.
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-12 | $0.24 | $-0.08 | 400.0 % |
Mar 2024 | 2024-05-15 | $-0.18 | $-0.10 | -80.0 % |
Dec 2023 | 2024-03-06 | $-0.24 | $-0.10 | -140.0 % |
Sep 2023 | 2023-11-08 | $-0.18 | $-0.15 | -20.0 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-12 | $128.23M | $38.48M | 233.2 % |
Mar 2024 | 2024-05-15 | $5.68M | $10.73M | -47.1 % |
Dec 2023 | 2024-03-06 | $231.00K | $20.47M | -98.9 % |
Sep 2023 | 2023-11-08 | $7.32M | $10.28M | -28.8 % |
Adaptimmune Therapeutics (ADAP) is scheduled to report earnings on November 6, 2024. The last reported earnings were for reported on August 12, 2024 for Q2.
The Actual EPS was $0.24, which beat the estimate of $-0.08.
The Actual Revenue was $128.2M, which beat the estimate of $38.5M.
Browse earnings estimates, EPS, and revenue on all stocks.